Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04983030 · ClinicalTrials.gov registry record · Phase 1

Safety, Immunogenicity, Efficacy of Ad26.Mos4.HIV, MVA-BN-HIV and PGT121, PGDM1400, and VRC07-523LS in HIV-1-Infected Adults

A Phase 1 study of HIV and Acquired Immunodeficiency Syndrome, sponsored by Boris Juelg, MD PhD.

Active
Registry status
Phase 1
Development phase
36
Enrollment target
6
Study locations

NCT04983030 is a Phase 1 study of HIV and Acquired Immunodeficiency Syndrome that is active but no longer recruiting, run by Boris Juelg, MD PhD. The registered enrollment target is 36 participants, below the 440-participant average among 303 other HIV trials with a reported enrollment target (92% lower). The trial reports 6 study locations across 6 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04983030, a Phase 1 study of HIV and Acquired Immunodeficiency Syndrome, is active but no longer recruiting, sponsored by Boris Juelg, MD PhD.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
36 participants
Enrollment target
6
Study locations

Study Summary

A multicenter, randomized, parallel-group, placebo-controlled, double-blind, Phase 1/2a clinical study to investigate the safety, tolerability, immunogenicity and exploratory efficacy of a vaccine regimen consisting of an Ad26.Mos4.HIV prime and a boost with Modified Vaccinia Ankara (MVA)-BN-HIV in combination with broadly neutralizing antibodies (bNAb) PGT121, PGDM1400, and VRC07-523LS in human immunodeficiency virus type 1 (HIV-1)-infected study participants on suppressive anti-retroviral therapy (ART).

Conditions Studied

HIV Acquired Immunodeficiency Syndrome Sexually Transmitted Diseases, Viral Retroviridae Infections Immunologic Deficiency Syndrome, Acquired

Interventions

  • BIOLOGICAL VRC07-523LS
  • BIOLOGICAL Ad26.Mos4.HIV
  • BIOLOGICAL MVA-BN-HIV
  • BIOLOGICAL PGT121
  • BIOLOGICAL PGDM1400

Study Locations (6)

California

  • UCLA CARE (Center for AIDs Research and Education) - Los Angeles

Florida

  • Orlando Immunology Center - Orlando

Massachusetts

  • Beth Israel Deaconess Medical Center - Boston

Missouri

  • Washington University Clinical Trials Unit - St Louis

Ohio

  • University Hospitals Cleveland Medical Center - Cleveland

Washington

  • University of Washington Positive Research - Seattle

Trial Details

FieldValue
Enrollment Target 36 participants
Start Date 2022-04-01
Est. Completion 2026-04-30
Phase Phase 1

Sponsor

Boris Juelg, MD PhD

1 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04983030

The ClinicalTrials.gov registry entry for NCT04983030 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 440-participant average among 303 other HIV trials with a reported enrollment target (92% lower). The listed sponsor is Boris Juelg, MD PhD, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 5 conditions, with HIV appearing as the primary indexed condition, and to 5 interventions - of which VRC07-523LS is the first listed.

NCT04983030 reports 6 study locations spanning 6 distinct geographic areas - top geographies include California, Florida, Massachusetts.

Frequently Asked Questions

What is clinical trial NCT04983030 about?

NCT04983030 is a clinical study titled "Safety, Immunogenicity, Efficacy of Ad26.Mos4.HIV, MVA-BN-HIV and PGT121, PGDM1400, and VRC07-523LS in HIV-1-Infected Adults". A multicenter, randomized, parallel-group, placebo-controlled, double-blind, Phase 1/2a clinical study to investigate the safety, tolerability, immunogenicity and exploratory efficacy of a vaccine regimen consisting of an Ad26.Mos4.HIV prime and a boost with Modified Vaccinia Ankara (MVA)-BN-HIV in ...

What is the current status of trial NCT04983030?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2022-04-01. Estimated completion is 2026-04-30.

What conditions does trial NCT04983030 study?

This clinical trial studies the following conditions: HIV, Acquired Immunodeficiency Syndrome, Sexually Transmitted Diseases, Viral, Retroviridae Infections, Immunologic Deficiency Syndrome, Acquired.

What interventions are being tested in trial NCT04983030?

The interventions under investigation include: VRC07-523LS (BIOLOGICAL), Ad26.Mos4.HIV (BIOLOGICAL), MVA-BN-HIV (BIOLOGICAL), PGT121 (BIOLOGICAL), PGDM1400 (BIOLOGICAL).

Who is sponsoring clinical trial NCT04983030?

This trial is sponsored by Boris Juelg, MD PhD, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04983030 being conducted?

This trial has 6 study locations across California, Florida, Massachusetts, Missouri, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for HIV

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

HIV

All registered trials for this condition

Acquired Immunodeficiency Syndrome

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.